ZA941176B - Cognition-enhancing selective adenosine receptor agents - Google Patents
Cognition-enhancing selective adenosine receptor agentsInfo
- Publication number
- ZA941176B ZA941176B ZA941176A ZA941176A ZA941176B ZA 941176 B ZA941176 B ZA 941176B ZA 941176 A ZA941176 A ZA 941176A ZA 941176 A ZA941176 A ZA 941176A ZA 941176 B ZA941176 B ZA 941176B
- Authority
- ZA
- South Africa
- Prior art keywords
- cognition
- adenosine receptor
- pct
- selective adenosine
- receptor agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA941176B true ZA941176B (en) | 1994-09-20 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA941176A ZA941176B (en) | 1993-02-26 | 1994-02-21 | Cognition-enhancing selective adenosine receptor agents |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0686155B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPH08512281A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100315898B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1041418C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE169019T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU680241B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2155130C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69412073T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0686155T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2120025T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUT72677A (cg-RX-API-DMAC7.html) |
| IL (1) | IL108750A (cg-RX-API-DMAC7.html) |
| MX (1) | MX9401406A (cg-RX-API-DMAC7.html) |
| NO (1) | NO311920B1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ262984A (cg-RX-API-DMAC7.html) |
| TW (1) | TW261532B (cg-RX-API-DMAC7.html) |
| WO (1) | WO1994019349A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA941176B (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998041237A1 (en) * | 1997-03-18 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Preventives and remedies for hyperphosphatemia |
| JP4611524B2 (ja) | 1998-06-02 | 2011-01-12 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ピロロ［２，３ｄ］ピリミジン組成物およびその使用 |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| ATE446298T1 (de) | 2001-11-30 | 2009-11-15 | Osi Pharm Inc | Verbindungen, die für adenosin a1 und a3 rezeptoren spezifisch sind, und deren anwendungen |
| EA007468B1 (ru) | 2001-12-20 | 2006-10-27 | Оси Фармасьютикалз, Инк. | Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение |
| US6846958B2 (en) * | 2002-05-15 | 2005-01-25 | Genzyme Corporation | Synthesis of benzimidate from benzoic acid |
| WO2004086047A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) |
| BRPI0417241A (pt) * | 2003-12-09 | 2007-03-06 | Kyowa Hakko Kogyo Kk | agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmo |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| WO2007095161A2 (en) * | 2006-02-14 | 2007-08-23 | New York University | Methods and compositions for treating disorders associated with increased bone turnover and osteopenia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8817122U1 (de) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active Expired - Fee Related
- 1994-01-27 EP EP94910661A patent/EP0686155B1/en not_active Expired - Lifetime
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-01-27 CA CA002155130A patent/CA2155130C/en not_active Expired - Fee Related
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/en not_active Ceased
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU680241B2 (en) | 1997-07-24 |
| EP0686155B1 (en) | 1998-07-29 |
| DK0686155T3 (da) | 1999-02-01 |
| DE69412073T2 (de) | 1999-02-18 |
| CA2155130A1 (en) | 1994-09-01 |
| JPH08512281A (ja) | 1996-12-24 |
| CN1041418C (zh) | 1998-12-30 |
| NO953353L (no) | 1995-08-25 |
| MX9401406A (es) | 1994-08-31 |
| EP0686155A1 (en) | 1995-12-13 |
| ES2120025T3 (es) | 1998-10-16 |
| TW261532B (cg-RX-API-DMAC7.html) | 1995-11-01 |
| CA2155130C (en) | 1994-09-01 |
| KR100315898B1 (ko) | 2002-02-28 |
| CN1118599A (zh) | 1996-03-13 |
| ATE169019T1 (de) | 1998-08-15 |
| NZ262984A (en) | 1997-05-26 |
| US5840729A (en) | 1998-11-24 |
| HU9502495D0 (en) | 1995-10-30 |
| DE69412073D1 (de) | 1998-09-03 |
| WO1994019349A1 (en) | 1994-09-01 |
| NO311920B1 (no) | 2002-02-18 |
| IL108750A0 (en) | 1994-05-30 |
| HUT72677A (en) | 1996-05-28 |
| NO953353D0 (no) | 1995-08-25 |
| AU6296894A (en) | 1994-09-14 |
| IL108750A (en) | 2000-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL117848A0 (en) | Novel compounds a process for their production and pharmacetical compositions containing same | |
| NO952229D0 (no) | Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader | |
| EP0573568A4 (en) | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system | |
| DE69611377D1 (de) | 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor | |
| CA2094716A1 (en) | Back support for a chair or seat | |
| ZA946142B (en) | Therapeutic heterocycles | |
| EP0509019A4 (en) | Treatment of human retroviral infections with 2',3'-dideoxyinosine | |
| GR3029396T3 (en) | Cosolvent parenteral formulation of tirilazad | |
| TW261513B (cg-RX-API-DMAC7.html) | ||
| IL108750A0 (en) | Cognition-enhancing selective adenosine receptor agents | |
| TW283647B (cg-RX-API-DMAC7.html) | ||
| GR3025698T3 (en) | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES. | |
| DE68918944D1 (de) | Künstliche rezeptor-analoge. | |
| DE3879535D1 (cg-RX-API-DMAC7.html) | ||
| GR3005566T3 (cg-RX-API-DMAC7.html) | ||
| GB9507883D0 (en) | Compounds | |
| SE9404438D0 (sv) | New process | |
| IL104817A0 (en) | Sugar derivatives of macrolides | |
| IL107917A0 (en) | Triazoloquinazolines, their preparation and their use as medicaments | |
| 胡金生 | Acupuncture Treatment of Dizziness and Vertigo | |
| HU9500709D0 (en) | Optically active hydroquinine (amino-3-phenyl)-1-ethanesulfonate, preparation and use thereof | |
| NZ304823A (en) | Beta carboline derivatives and medicaments | |
| GR3027682T3 (en) | 4-guanidinobutyramide for improving blood circulation. |